SARS-CoV 2
Conditions
Keywords
SARS-CoV2, cohort, containment, serology, prevention
Brief summary
This study aims to quantify and follow the cumulative incidence of SARS-CoV-2 infection in the French population using serological tests and to assess the determinants of infection from Constances, E3N-E4N, ELFE-Epipage 2 and NutriNet-Santé cohorts.
Detailed description
The primary objective is to assess the cumulative incidence of infection in the general population using dried blood spot sampling. The secondary objectives are: * To identify factors associated with a positive SARS-CoV-2 infection (positive serology) and to characterize the durability of the serological response to SARS-CoV-2 * To identify associations of symptoms predictive of a SARS-CoV-2 infection * To estimate the health care use associated with a SARS-CoV-2 infection * To estimate the fraction of sub-clinical infections or infections not captured by the healthcare system; * To study the acceptability of a mass anti-SARS-CoV-2 serological testing and the impact of its result, linked with social inequalities in health; * To estimate the individual and collective impact of containment and other preventive measures on the risk of SARS-CoV-2 infection; * To study the impact of social and territorial inequalities on seroprevalence levels.
Interventions
BIOLOGICALNon applicable
to collect data from questionnaires and to collect serological samples
Sponsors
Institut National de la Santé Et de la Recherche Médicale, France
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* non applicable, already enrolled in the cohorts
Exclusion criteria
* non applicable
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cumulative incidence of SARS-Cov2 infection in the general population. | 8 months | Simple and corrected estimate of the number of seropositive individuals/number of individuals at risk in different strata, based on weighting and calibration and taking into account the random cohort effect. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of use of care (medical care, hospitalization, center 15) linked to the occurrence of symptoms suggestive of a SARS-Cov2 infection, and share attributable to the infection | 8 months | Rate of use of care (medical care, hospitalization, center 15) linked to the occurrence of symptoms suggestive of a SARS-Cov2 infection, and share attributable to the infection during a time frame of 8 months |
| Proportion of infections without reported or pauci-symptomatic symptoms and their epidemiological and social determinants | 8 months | Proportion of infections without reported or pauci-symptomatic symptoms and their epidemiological and social déterminants during a time frame of 8 months. |
| Maintenance over time of the acquisition of anti-SARS-Cov2 antibodies | 8 months | Decay kinetics estimated by mixed effect model with repeated data per subject |
| Proportion and intensity of use of barrier measures (hydroalcoholic gel, mask, social distancing, description of outings / reasons, duration, frequency) and association with the level of seroprevalence | 8 months | Proportion and intensity of use of barrier measures (hydroalcoholic gel, mask, social distancing, description of outings / reasons, duration, frequency) and association with the level of seroprevalence during a time frame of 8 months |
| Strengths of associations between socio-behavioral factors and level of seroprevalence | 8 months | Strengths of associations between socio-behavioral factors and level of seroprevalence during a time frame of 8 months |
| Proportion of tests proposed, accepted, performed, based on social and demographic characteristics | 8 months | Proportion of tests proposed, accepted, performed, based on social and demographic characteristics during a time frame of 8 months. |
Countries
France
Outcome results
None listed